Trial Profile
A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aderbasib (Primary) ; Docetaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Incyte Corporation
- 07 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 20 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.